Tower Research Capital (TRC)’s Tempest Therapeutics TPST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.58K | Buy |
2,790
+1,465
| +111% | +$3.54K | ﹤0.01% | 4182 |
|
|
2025
Q4 | $3.8K | Buy |
+1,325
| New | +$9.37K | ﹤0.01% | 4311 |
|
|
2025
Q1 | – | Sell |
-840
| Closed | -$9.12K | – | 5791 |
|
|
2024
Q4 | $9.12K | Buy |
840
+376
| +81% | +$4.85K | ﹤0.01% | 3939 |
|
|
2024
Q3 | $8.45K | Buy |
464
+463
| +46,300% | +$9.48K | ﹤0.01% | 3963 |
|
|
2024
Q2 | $33 | Sell |
1
-614
| -100% | -$26.6K | ﹤0.01% | 5557 |
|
|
2024
Q1 | $31.3K | Buy |
615
+532
| +641% | +$26.9K | ﹤0.01% | 2616 |
|
|
2023
Q4 | $4.73K | Sell |
83
-950
| -92% | -$45K | ﹤0.01% | 4922 |
|
|
2023
Q3 | $4.1K | Buy |
1,033
+365
| +55% | +$3.5K | ﹤0.01% | 4918 |
|
|
2023
Q2 | $11K | Buy |
668
+3
| +0.5% | +$76 | ﹤0.01% | 4029 |
|
|
2023
Q1 | $20K | Buy |
665
+158
| +31% | +$3.46K | ﹤0.01% | 3451 |
|
|
2022
Q4 | $8K | Buy |
507
+148
| +41% | +$3.12K | ﹤0.01% | 4460 |
|
|
2022
Q3 | $8K | Buy |
359
+125
| +53% | +$3.71K | ﹤0.01% | 4814 |
|
|
2022
Q2 | $7K | Buy |
234
+67
| +40% | +$2.6K | ﹤0.01% | 4830 |
|
|
2022
Q1 | $7K | Sell |
167
-44
| -21% | -$2K | ﹤0.01% | 4769 |
|
|
2021
Q4 | $15K | Buy |
+211
| New | +$29.1K | ﹤0.01% | 4008 |
|
|
2021
Q3 | – | Sell |
-45
| Closed | -$6K | – | 6175 |
|
|
2021
Q2 | $6K | Buy |
+45
| New | +$10.1K | ﹤0.01% | 4644 |
|
|
2021
Q1 | – | Sell |
-13
| Closed | -$5K | – | 5732 |
|
|
2020
Q4 | $5K | Sell |
13
-9
| -41% | -$3.11K | ﹤0.01% | 4643 |
|
|
2020
Q3 | $7K | Buy |
22
+7
| +47% | +$2.37K | ﹤0.01% | 4253 |
|
|
2020
Q2 | $5K | Hold |
15
| – | – | ﹤0.01% | 4299 |
|
|
2020
Q1 | $15K | Sell |
15
-16
| -52% | -$23.3K | ﹤0.01% | 1850 |
|
|
2019
Q4 | $40K | Buy |
+31
| New | +$43.7K | ﹤0.01% | 1478 |
|
|
2019
Q3 | – | Sell |
-2
| Closed | -$4K | – | 4513 |
|
|
2019
Q2 | $4K | Buy |
+2
| New | +$5.89K | ﹤0.01% | 3052 |
|
|
2019
Q1 | – | Sell |
-4
| Closed | -$7K | – | 4278 |
|
|
2018
Q4 | $7K | Buy |
+4
| New | +$8.23K | ﹤0.01% | 2717 |
|
|
2018
Q3 | – | Sell |
-6
| Closed | -$16K | – | 4248 |
|
|
2018
Q2 | $16K | Buy |
6
+5
| +500% | +$13.2K | ﹤0.01% | 2564 |
|
|
2018
Q1 | $3K | Buy |
+1
| New | +$3K | ﹤0.01% | 2881 |
|
|
2017
Q4 | – | Sell |
-1
| Closed | -$4K | – | 4022 |
|
|
2017
Q3 | $4K | Buy |
+1
| New | +$4.28K | ﹤0.01% | 3414 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 3445 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 3910 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 4397 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 3370 |
|
|
2016
Q2 | – | Sell |
-1
| Closed | -$22.8K | – | 3296 |
|
|
2016
Q1 | $29K | Buy |
+1
| New | +$21.1K | ﹤0.01% | 1095 |
|
|
2015
Q4 | – | Sell |
-8
| Closed | -$264K | – | 2825 |
|
|
2015
Q3 | $194K | Buy |
8
+7
| +700% | +$471K | 0.02% | 297 |
|
|
2015
Q2 | $85K | Sell |
1
-1
| -50% | -$91.6K | 0.01% | 977 |
|
|
2015
Q1 | $175K | Buy |
+2
| New | +$266K | 0.02% | 491 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 2609 |
|
|
2014
Q2 | – | Sell |
-1
| Closed | -$14K | – | 4640 |
|
|
2014
Q1 | $14K | Buy |
+1
| New | +$28.3K | ﹤0.01% | 2270 |
|
|
2013
Q4 | – | Hold |
0
| – | – | – | 3539 |
|
|
2013
Q3 | – | Hold |
0
| – | – | – | 4849 |
|
|
2013
Q2 | – | Hold |
0
| – | – | – | 2138 |
|
Other funds holding TPST
VVM
VCM
VFT
SM
Tower Research Capital (TRC)'s TPST Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its Tempest Therapeutics (TPST) stake by 111% in Q1 2026, buying an estimated $3.54K and bringing the position to 2,790 shares worth $4.58K. The position accounts for ﹤0.01% of the portfolio, ranked #4182.
Tower Research Capital (TRC) first reported a position in TPST in Q1 2014 and has held it in 31 quarters since. The position peaked at $194K in Q3 2015. 22 funds tracked by Wall St. Rank hold TPST as of Q1 2026.
- Tower Research Capital (TRC) held 2,790 shares of Tempest Therapeutics worth $4.58K as of Q1 2026.
- Tower Research Capital (TRC) bought 1,465 Tempest Therapeutics shares in Q1 2026, an estimated $3.54K.
- Tempest Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4182 holding.
- Tower Research Capital (TRC) first reported a position in Tempest Therapeutics in Q1 2014 and has held it in 31 quarters since.
- Tower Research Capital (TRC)'s Tempest Therapeutics position peaked at $194K in Q3 2015.
- 22 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.